Status:
COMPLETED
Observational Study With Mixtard® 30 NovoLet® to Assess Patient Satisfaction
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 1
Eligibility:
All Genders
Brief Summary
This study is conducted in Asia. The aim of this study is to assess patient satisfaction after switching to biphasic human insulin 30 treatment using the NovoLet® insulin device as treatment for diabe...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Diabetes mellitus (type 1 or type 2)
- Patient not presently using Mixtard® 30 NovoLet®
Exclusion
Key Trial Info
Start Date :
March 15 2004
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 30 2004
Estimated Enrollment :
1330 Patients enrolled
Trial Details
Trial ID
NCT01492218
Start Date
March 15 2004
End Date
August 30 2004
Last Update
February 28 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Manila, Philippines, 1605